

Phylogenetic analysis of HIV-1 archived DNA in blood and gut-associated lymphoid tissue in patients receiving antiretroviral therapy: a study from Provir/Latitude45 project.

Patricia Recordon-Pinson¹, Camille Tumiotto¹, Pantxika Bellecave¹, Franck Salin², Patricia Thebault³, Annie Gosselin⁴

Petronela Ancuta⁵, Marcelo Soares⁶, Jean-Pierre Routy⁷ and Hervé Fleury^{1*}

¹University Hospital of Bordeaux and CNRS UMR 5234, Bordeaux, France ²Plateforme Génome Transcriptome de Bordeaux, INRA Pierroton, Cestas, France; ³LaBRI, Université de Bordeaux, Talence, France; ⁴Centre Hospitalier Universitaire de Montreal (CHUM) Research Centre, Montréal, QC, Canada; ⁵Département de Microbiologie, Infectiologie et Immunologie, Faculté de Médecine, Université de Montréal, Montréal, QC, Canada; ⁶Oncovirology Program, Instituto Nacional de Câncer, Rio de Janeiro, Brazil; ⁷Chronic Viral Illness Service and Division of Hematology, McGill University Health Centre Montreal, QC, Canada

*Correspondence : herve.fleury@u-bordeaux.fr

Abstract

One of the approaches to cure HIV is the use of therapeutic vaccination. We have launched the Provir/Latitude 45 study to identify conserved CTL epitopes in archived HIV-1 DNA according to the HLA class I alleles in aviremic patients under antiretroviral therapy (ART). A HIV-1 polypeptidic therapeutic vaccine based on viral sequence data obtained from circulating blood was proposed; here, our aim was to compare the proviral DNA in blood and gut-associated lymphoid tissue (GALT) at two different levels : nucleotide sequences and potential CTL epitopes. The reverse transcriptase was sequenced in both compartments using next generation sequencing (NGS) in samples from nine individuals, two of which had also single genome sequencing (SGS) performed; phylogenetic trees were established and compared ; CTL epitopes were also identified according to their potential affinity for the HLA alleles . The proviral sequences of both compartments intra-patient exhibited a very low genetic divergence while it was possible to differentiate the sequences inter-patients; SGS analysis of two couples of samples confirmed that there was not a compartmentalization of the sequences intra-patient. When we simulated the CTL epitopes which can be presented by the corresponding HLA alleles in both compartments, no significant difference was observed. We conclude that the proviral DNA sequences in blood and GALT are similar and that the epitope analysis in blood can be considered as relevant to that observed in the GALT, a hard-to-reach major compartment, and can therefore be used for therapeutic vaccine approaches.

Keywords

HIV-1, proviral DNA, blood, gut associated lymphoid tissue (GALT), CTL epitopes, phylogenetic comparison of archived viral sequences

Introduction

HIV-1 infection can be treated with ART, leading to the control of viral replication and improving the health of people living with HIV (PLWH). However, ART cannot be interrupted since this would lead to a rebound of viral replication [1,2] as virus establishes cellular (latently infected resting CD4+ memory T cells) and anatomical reservoirs very early during infection [3-8]. Gut Associated Lymphoid Tissue (GALT) is considered to be one of the main reservoirs of SIV and HIV infection [9-11]. Cure strategies for HIV-1 include therapeutic vaccination [12], although immune response observed was not able to control viral replication after ART discontinuation [13]. In this context, we launched the Provir/Latitude 45 project to identify conserved CTL epitopes in the proviral HIV-1 DNA of patients with long-term ART. The study involves *in silico* modeling based on the HIV-1 proviral DNA sequences, the HLA alleles and the HIV-1 CTL epitopes recorded in the Los Alamos database and the Immune Epitope database (IEDB) simulator following sequencing of the archived DNA from peripheral blood mononuclear cells (PBMC), i.e. from circulating blood. Since our initial work was based on proviral DNA in PBMC, we assessed whether our observations would be the same in another compartment, namely GALT. Herein, we present a phylogenetic comparison of the archived HIV-1 DNA in PBMC and GALT from patients at success of ART, together with an evaluation of theoretically conserved CTL epitopes in both compartments.

Results

Phylogenetic trees of intra-patient and inter-patient samples

GALT and PBMC proviral DNA samples obtained from nine patients were sequenced by NGS. The phylogenetic trees of all samples are presented in Figure 1; NGS intra-patient sequences from blood and GALT compartments analyses exhibit a low genetic divergence and are located on the same branch. When analyzing simultaneously the data from two patients (5A and 10) (Figure2) we are able, as expected, to differentiate viral sequences originating from the two patients. As a slight discrimination between PBMC and GALT samples was observed when considering NGS sequences, we carried out a SGS analysis of samples 5A and 10 (PBMC and GALT) to check a potential artefactual role of the amplification process on the discrimination between both compartments. As shown in Figure 2, this analysis

indicates that there was a true intermingling of the clonal sequences for patient 5A, evidencing lack of compartmentalization. For patient 10, the clonal PBMC sequences were located at the origin of the GALT NGS part of the tree (please refer to Figure 1) , then found in the PBMC part of the NGS tree while GALT clonal sequences were located at the end of the GALT tree and the origin of the PBMC tree; as for patient 5A we can conclude that there is no evidence of compartmentalization.

To confirm that all the sequences were clustered by patient, we estimated the evolutionary divergence between sequences (Table 1) considering patients 5A and 10 . HIV-1 clusters were identified at maximum genetic distances between 4.5% and 7.5% and bootstrap support threshold varied between 70% and 99% [14]. As sequences from patients 5A and 10 are assembled with a median divergence of 5.3% and 2.2% respectively with bootstrap values of 80% and 93%, we confirm that these sequences from GALT and PBMC formed a specific cluster per patient.

Table1: Estimates of evolutionary divergence between patients' HIV proviral DNA sequences. Evolutionary divergences are based on the number of base substitutions per site among RT NGS and/or SGS sequences obtained from GALT and/or PBMC proviral DNA of patients 5A and 10. nd: not done

		Patient 05A		Patient 10		Patients 5A + 10	
		Median [min-max]	Mean	Median [min-max]	Mean	Median [min-max]	Mean
GALT	NGS	0.030 [0-0.189]	0.029	0.016 [0-0.098]	0.016	nd	nd
	SGS	0.055 [0-0.088]	0.047	0.005 [0-0.013]	0.005	nd	nd
	NGS+ SGS	0.061 [0-0.119]	0.054	0.011 [0-0.065]	0.012	nd	nd
PBMC	NGS	0.053 [0-0.145]	0.051	0.013 [0-0.061]	0.013	nd	nd
	SGS	0.047 [0-0.122]	0.051	0.013 [0-0.030]	0.013	nd	nd
	NGS+ SGS	0.065 [0.013-0,132]	0.065	0.016 [0-0.057]	0.017	nd	nd

GALT							
+	NGS	0.053 [0.008-0.143]	0.054	0.022 [0.003-0.095]	0.022	0.08 [0.047-0.214]	0.085
PBMC							

CTL epitopes with affinity for HLA alleles

The epitopes selected by our simulation pipeline have a high theoretical affinity for the HLA alleles of the patients.

We compared the inhibitory concentration 50 (IC₅₀) values for each epitope based on its PBMC and GALT proviral

sequences. An example is presented in Table 2. In the case of the RT (18-26) epitope, there was one variant in GALT

and two in PBMC with a conserved very low IC₅₀, making it possible to predict a high affinity for the B*08:01 allele.

For the second epitope RT (158-166), there were two variants in both compartments. All variants were different with

one in GALT at 44.89% (AIFQSSMTQ) exhibiting an IC₅₀ largely >500 nanomolar (nM) (2203.8nM) and therefore

having no affinity for the A*03:01 allele.

Combining all the data for the nine patients of the study and taking into account their various HLA I alleles A and B

plus the obtained DNA sequences in both compartments, we found that 23 epitopes had affinity for the following

alleles: A*02:01, A*03:01, A*11:01, B*08:01, B*35:01, B*40:01, B*07:02 (all data available in Table S1). The number

of variants per compartment ranged from one to three. There was no significant difference in the number of variants

between GALT and PBMC (Wilcoxon test p-value=0.6239). The number of epitopes exhibiting a variant with an IC₅₀

>500nM was limited to one sample (please refer to the example above and to Table S1), so the variability in the

compartments may not be associated with a defect on presentation of the epitopes by the alleles.

Table 2 : Examples of RT epitopes with theoretical affinity for the HLA alleles of the patients. Positions precise RT

amino-acids involved. The numbers of reads and their percentage (%) relative to the total number of reads covering

the targeted region are related to NGS results. The Inhibitory concentrations IC₅₀ (nM) that reflect the affinity of the

epitopes for the HLA alleles-were automatically calculated using TutuGenetics software. The modified amino-acids in

the epitopes versus the reference sequence from the Los Alamos database are in bold character and underlined.

When > 500 nM the IC₅₀ is noted in bold italic.

Position	HLA allele	Compartment	Epitope sequence	Number of reads	Reads (%)	IC ₅₀ (nM)
----------	------------	-------------	---------------------	--------------------	-----------	-----------------------

RT(18-26)	HLA-B*08:01	GALT	GPKVKQWPL	78287	87.73%	41.5
		PBMC	GPKVKQWPL	11562	87.66%	41.5
			GPK <u>A</u> KQWPL	233	1.77%	50.5
RT(158-166)	HLA-A*03:01	GALT	AIFQSSMTK	48154	44.22%	12.8
			AIFQSSMT <u>Q</u>	48889	44.89%	2203.8
		PBMC	AIFQSSM <u>I</u> K	30329	84.62%	13.9
			AIF <u>R</u> SSM <u>I</u> K	444	1.24%	8.7

Discussion

Archived viral DNA is found in intestinal tissue at a higher concentration than in PBMCs in ART patients [15], although the distribution of DNA in CD4+ CCR7+, transitional memory and effector memory T cells is different in blood and intestinal compartments [16]. GALT is therefore a compartment of major importance in the pathophysiology of HIV infection [17,18]. The data presented here are not related to the quantification of archived DNA but rather to a comparison of the RT sequences obtained by NGS in GALT and PBMC. In that regard, Van Marle et al. [19] have studied biopsies from infected untreated individuals and sequenced the nef and RT genes of the viral RNA from blood (PBMC) and different parts of the gut by cloning and Sanger sequencing ; they concluded that there is a compartmentalization of the virus in the gut reservoir. On the other hand, Lerner et al [20] found a low diversity of the GALT and PBMC viruses in patients having experienced a voluntary treatment interruption while Imamichi et al [21] did not demonstrate any difference between RNA and DNA sequences from gut and blood of patients chronically infected with HIV-1. Studying HIV-1 infected patients at early and chronic infection stages, Rozera et al [22] found a more pronounced compartmentalization of proviral quasispecies in gut compared with PBMC samples in patients with early infection compared with chronic patients. The loss of gut/PBMC compartmentalization in more advanced stages of HIV infection was confirmed by longitudinal observation.

Regarding ART treated patients, Evering et al.[23] have studied the variability of the proviral DNA in the gut and blood compartments by SGS of the env part of the virus. They showed absence of evolution of the env sequences in the GALT and in PBMC; the authors mention that they cannot rule out the possibility of evolution in other viral genomic regions of HIV-1 such as pol which have not been investigated. Josefsson et al [24] have compared the HIV DNA in PBMC and GALT from patients being on successful ART; they have used SGS technology and showed that there is no significant difference between the sequences from both compartments. They concluded that the HIV reservoir is stable on long-term suppressive ART and raise the hypothesis that the population of infected cells exhibiting a low variability of the virus could be maintained by homeostatic cell proliferation.

The patients of our study are similar to those of the two publications mentioned above; they were long term ART-treated patients with controlled viral load and therefore a stable viral reservoir; the phylogenetic inferences obtained after NGS evidenced a very low genetic distance between the GALT and PBMC compartments intra-patient. On the other hand, it is possible to differentiate the GALT/PBMC sequences inter-patients; the SGS analysis performed for two samples, 5A and 10, plus the genetic divergence values after NGS and SGS are concordant with a high similarity between proviruses intra-patient. It must be underlined that the SGS technique decreases taq-induced recombination and nucleotide misincorporation, providing therefore a more reliable conclusion than conventional cloning [33].

Among the limitations of our study we must note the fact that only the RT part of the proviral DNA has been considered and also that we have analyzed global archived DNA molecules without differentiating noninfectious and replication competent genomes [34]; however, more recent data show that even defective proviral DNA molecules can be expressed and yield viral proteins recognized by CTL T CD8+ lymphocytes [35].

Provir/Latitude 45 project is based on the identification of conserved epitopes in the provirus with potential affinity for the dominant alleles of the population; therefore, more than 200 patients at successful ART have been investigated for these conserved epitopes [27] and a peptide cocktail has been proposed; it must be noted that this project is based on the study of the blood compartment and the question has been raised whether another compartment could yield different results; as the GALT is a major reservoir, we have then focused on a simulation of the CTL epitopes of the nine patients in both compartments with a high affinity for the corresponding HLA I alleles; having determined viral CTL epitopes in the blood compartment that should have a high affinity for the corresponding HLA A and B alleles of the patients individually, we have raised the question of a full identity or not of these epitopes in the gut compartment; a significant difference would be a hurdle for the vaccine strategy based on

the blood analysis; clearly, however, the differences between the two compartments are slight even if there are variants at the epitope locations (but with a close affinity for the HLA alleles); the global choice of the epitopes at the blood level seems therefore extrapolable to the GALT level. In conclusion, our results confirm that the proviruses in GALT and PBMC are very similar in these patients having experienced a long-term ART success and who could be the target population of choice for a therapeutic vaccine. They also provide new data on the high similarity of the CTL epitopes in both compartments according to their potential affinity for the HLA alleles of the patients investigated. Taken together, these results indicate that the analysis of the blood compartment can provide results that can be extrapolated to the gut compartment, a major reservoir of HIV. The strategies used in the future, whatever they might be, will have to eradicate the virus from the blood and also from the different tissue reservoirs including the gut.

Materials and Methods

Study participants

A total of nine PLWH were recruited at MUHC. Cells were isolated at the CHUM Research Centre, Montreal, Quebec, Canada. All participants were MSM infected with HIV-1 subtype B. They were under successful ART which had been initiated between at least one year up to 14 years after HIV infection, while biopsies were obtained between four to 26 years after ART initiation; the main HLA alleles of the series investigated were representative of a Caucasian population (among them HLA A*02:01 and B*07:02); detailed clinical information on study cohort participants has been previously published [28].

Sigmoid colon biopsies and blood cells

Sigmoid biopsies (≈ 32 biopsies/donor) were collected from HIV-infected individuals receiving ART during colonoscopy and processed using Liberase DL (Roche Diagnostics), as previously described (28). Matched peripheral blood (20 ml/donor) was collected on the same day from biopsy donors and immediately processed with Ficoll for PBMC isolation, performed in parallel with cell extraction from biopsy tissue.

Extraction of total HIV DNA

Cells from gut biopsies and PBMC were suspended in 350 μ L of RLT buffer with β -mercaptoethanol and total DNA was extracted using the Qiagen AllPrep DNA/RNA kit. The extracted DNA was then sent to Bordeaux University Hospital for further investigation.

Identification of HLA alleles

The method used for the molecular characterization of HLA alleles A and B in the Montreal cohort has been described previously [25]. Briefly, intermediate-to-high resolution sequencing of extracted DNA was performed by reverse Polymerase Chain Reaction-Sequence Specific Oligonucleotide (PCR-SSO) hybridization by using the LuminexH flow beads LabTypeH assay (InGen) for the A and B loci. Allelic ambiguities were resolved by PCR-Sequence Specific Primer (SSP) amplification by using Olerup assays. Allele assignment was performed by comparison with official nomenclature and validated by the WHO committee for HLA system factors. All HLA A and B alleles have been determined for all patients. They are presented and discussed in Table 2 and Table S1 only when their affinity for the reference epitopes exhibits an inhibitory concentration 50, $IC_{50} < 50nM$ (please refer to the subchapter Prediction of affinity between epitopes and HLA alleles using NGS data).

NGS of HIV proviral DNA

We used the method already published [29,30] to amplify fragment B, i.e. polymerase (Pol) region including RT and integrase. After DNA extraction, nested PCR was carried out with the following outer primers: 1st F ATGATAGGGGGAATTGGAGGTTT (HXB2 loci 2388-2410), 1st R CCTGTATGCAGACCCCAATATG (5264-5243), and inner primers 2nd F GACCTACACCTGTCAACATAATTGG (2485-2509), 2nd R CCTAGTGGGATGTGTACTTCTGAACTTA (5219-5192). The PCR products were purified and quantitated. The library was prepared using the Nextera XT DNA Sample Preparation kit. A purification step was performed and the library was quantified by TapeStation technology. Each individual library was then sequenced on a MiSeq Illumina platform. Raw data (FASTQ files) were submitted to the SmartGene® NGS HIV-1 module to generate a BAM file for each patient and each sample was processed for further analysis [31]. The study was carried out using only the Pol RT part region of the sequences obtained.

Phylogenetic analysis following NGS

Using Galaxy and Clustal software, RT gene sequences from the two compartments (GALT and PBMC) per patient were selected for neighbor-joining analysis from matrix distances calculated after gapstripping of alignments, with a Kimura two-parameter algorithm and bootstrap analysis. To do so, an alignment was generated that included only reads with lengths > 400 bp corresponding to a given region of RT (variable according to the patient, from amino-

acids 39 to 202). This length limitation explains the small number of reads used for this analysis compared to the total number of reads covering this region. Phylogenetic trees were visualized using ITOL (Interactive Tree of Life) software [32].

SGS and analysis

SGS was carried out using samples from two patients (5A and 10) according to the method of Palmer et al [33]. The total extracted DNA of both compartments was diluted in TE buffer at a dilution yielding a PCR product in 3 out of 10 PCRs. In this case, according to Poisson's distribution, the dilution contains 1 copy of cDNA per positive PCR at about 80% of the time. Two rounds of PCR for RT amplification were followed by visualization of the PCR products by capillary electrophoresis using QIAxcel DNA screening kit. The 1:9 dilution was found to be optimal for Sanger sequencing and the sequences (assuming that there was no mixture of population) of PBMC and GALT obtained were aligned by Clustal to obtain a neighbor-joining tree.

Prediction of affinity between epitopes and HLA alleles using NGS data

The TutuGenetics software [36] allows the automatic identification of CTL epitopes that can theoretically be presented by the HLA I alleles of the patients. It links the sequence data, the identity of the HLA alleles, the Los Alamos HIV database for CTL epitopes and the International Immune Epitope Database (IEDB) simulator. It does not only identify CTL epitopes in the LANL database but also proposes predictive epitopes as previously published [27]. Using the TutuGenetics software, the theoretical affinity between the CTL epitopes encoded in the RT region and the HLA alleles of each patient at both compartments was calculated. We focused only on those epitopes that had a theoretical affinity for a defined allele of the patient with an MHC $IC_{50} < 50nM$. When variants were identified, they were evaluated for their $IC_{50} < 50nM$ or in ranges between 50-500 nM. It should be noted that the number of reads analyzed was higher since only variants present at a frequency $> 1\%$ at a given position of the CTL epitopic peptide sequence were considered.

Evolutionary divergence and statistical analysis

The median, mean and range of the number of base substitutions per site between RT sequences were calculated. Analyses were conducted using the Maximum Composite Likelihood model [37]. The analysis involved 4100 nucleotide sequences. Codon positions included were 1st+2nd+3rd+Noncoding. All positions containing gaps and missing data were eliminated. There were a total of 376 positions in the final dataset. Evolutionary analyses were conducted in MEGA7 [38].

The Wilcoxon test was used for analysis of the number of variants at the different positions of epitopes with a theoretical affinity for defined alleles within both compartments; the IC₅₀ values considered were <500nM and >500nM.

List of abbreviations

GALT: gut associated lymphoid tissue; NGS: next generation sequencing; PLWH: people living with HIV; PBMC: peripheral blood mononuclear cells; IC₅₀ : inhibitory concentration 50; SGS: single genome sequencing; Pol: polymerase; RT: reverse transcriptase; ART: antiretroviral therapy

Declarations

Ethics: this study using colon biopsies and blood from patients living with HIV (PLWH) was approved by the Research Ethics Boards of the Research Institute of McGill University Health Centre (MUHC), Montreal, QC, Canada and the Centre Hospitalier de l'Université de Montréal (CHUM) Research Centre, Montréal, QC, Canada. The study also received approval from the Comité d'Ethique du Sud Ouest et Outremer (DC 2012/48) and was conducted in accordance with the Declaration of Helsinki. Each participant provided written informed consent before any study procedure.

Availability of data: the NGS sequences are available in GenBank under accession number PRJN557560; the Sanger sequences of the SGS study are available in GenBank under accession numbers MN250226 to MN250287

Competing interests: the authors declare that they have no competing interests

Funding: the study was funded by a grant from MSD Avenir (DS-2016-005) and a financial contribution from GERMATAN (Groupe d'Etude et de Recherche sur les Maladies Animales Transmissibles et les Anthropozoonoses). Sequencing of proviral DNA by Illumina technology was performed at the Genome Transcriptome Facility in Bordeaux (grants from the Conseil Régional d'Aquitaine n°20030304002FA and 20040305003FA, from the European Union FEDER n°2003227 and from Investissements d'Avenir ANR-10-EQPX-16-01)

Authors' contributions: HF designed the study, found the main source of funding (MSD Avenir) and wrote the manuscript with the help of PP and contributions from MS, PA and JPR; JPR recruited the patients; PP, CT, PB, FS, PT, and AG executed technical parts of the study and were involved in analysis of the data. All authors read and approved the final manuscript.


Acknowledgments: we thank Lucie Richard, an engineering student at the university of Bordeaux, for her excellent technical collaboration. The valuable advices and comments by Z Brumme (British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada) were greatly appreciated.

We would like to thank Maria Fraraccio for her administrative support in Montreal and Frédéric Perry for his administrative assistance at the DRCI CHU in Bordeaux. Ray Cooke is also thanked for copyediting.


References

1. Chun T-W, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA, Fauci, AS. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. *Proc. Natl. Acad. Sci. U. S. A.* 1997; *94*: 13193–13197.
2. Chun T-W, Justement JS, Murray D, Hallahan CW, Maenza J, Collier AC, Sheth PM, Kaul R, Ostrowski M, Moi S, Kovacs C, Fauci AS . Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. *AIDS.* 2010; *24*: 2803–2808.
3. Finzi D, Hermankova M., Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. *Science* 1997;*278*: 1295–1300.
4. Chun T-W, Fauci AS. Viral persistence in HIV infection: much known, much to learn. *J. Infect. Dis.* 2013; *208* : 1356–1358.
5. Chun T-W, Moir S, Fauci AS . HIV reservoirs as obstacles and opportunities for an HIV cure. *Nat. Immunol.* 2015; *16*: 584–589.
6. Wong JK, Yukl SA . Tissue reservoirs of HIV. *Curr. Opin. HIV AIDS* 2016; *11*: 362–370.
7. Barton K, Winckelmann A, Palmer S. HIV-1 Reservoirs During Suppressive Therapy. *Trends Microbiol.*2016; *24*: 345–355.
8. Miller RL, Ponte R, Jones BR, Kinloch NN, Omondi FH, Jenabian M-A, Dupuy FP, Fromentin R, Brassard P, Mehraj V, Chomont N, Poon AFY, Brumme ZL, Routy J-P and the ORCHID study group. HIV diversity and genetic compartmentalization in blood and testes during suppressive antiretroviral therapy. *J. Virol.* 2019; 10.1128/JVI.00755-19
9. Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, Roederer M . Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. *Nature* 2005;*434*: 1093–1097.
10. Chun T-W, Nickle DC, Justement JS, Meyers JH, Roby G, Hallahan CW, Kottlilil S, Moir S, Mican JM, Mullins JI, Ward DJ, Kovacs JA, Mannon PJ, Fauci AS. . Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. *J. Infect. Dis.* 2008; *197*: 714–720.
11. Estes JD, Kityo C, Ssali F, Swainson L, Makamdop KN, Del Prete GQ, Deeks SG, Luciw PA, Chipman JG, Beilman GJ, Hoskuldsson T, Khoruts A, Anderson J, Deleage C, Jasurda J, Schmidt TE, Hafertepe M, Callisto SP, Pearson H, Reimann T, Schuster J, Schoephoerster J, Southern P, Perkey K, Shang L, Wietgreffe SW, Fletcher CV, Lifson JD, Douek DC, McCune JM, Haase AT, Schacker TW . Defining total-body AIDS-virus burden with implications for curative strategies. *Nat. Med.* 2017;*23*: 1271–1276.
12. Deeks SG, Lewin SR, Ross AL, Ananworanich J, Benkirane M, Cannon P, Chomont N, Douek D, Lifson JD, Lo Y-R., Kuritzkes D, Margolis D, Mellors J, Persaud D, Tucker JD, Barre-Sinoussi F; International AIDS Society Towards a Cure Working Group, Alter G, Auerbach J, Autran B, Barouch DH, Behrens G, Cavazzana M, Chen Z, Cohen ÉA, Corbelli GM, Eholié S, Eyal N, Fidler S, Garcia L, Grossman C, Henderson G, Henrich TJ, Jefferys R, Kiem HP, McCune J, Moodley K, Newman PA, Nijhuis M, Nsubuga MS, Ott M, Palmer S, Richman D, Saez-Cirion A, Sharp M, Siliciano J, Silvestri G, Singh J, Spire B, Taylor J, Tolstrup M, Valente S, van Lunzen J, Walensky R, Wilson I, Zack J . International AIDS Society global scientific strategy: towards an HIV cure *Nat. Med.* 2016; *22*: 839–850.
13. Fleury H, Tumioto C, Bellecave P, Recordon-Pinson P . Therapeutic Vaccine Against HIV, Viral Variability, Cytotoxic T Lymphocyte Epitopes, and Genetics of Patients. *AIDS Res. Hum. Retroviruses* 2018;*34*: 27–30.
14. Ragonnet-Cronin M, Hodcroft E, Hué S, Fearnhill E, Delpech V, Brown AJ, Lycett S; UK HIV Drug Resistance Database . Automated analysis of phylogenetic clusters. *BMC Bioinformatics* 2013;*6*:14:317
15. Moron-Lopez S, Puertas MC, Galvez C, Navarro J, Carrasco A, Esteve M, Manye J, Crespo M, Salgado M, Martinez-Picado J. . Sensitive quantification of the HIV-1 reservoir in gut-associated lymphoid tissue. *PloS One* 2017;*12*: e0175899.
16. Yukl SA, Shergill AK, Ho T, Killian M, Girling V, Epling L, Li P, Wong LK, Crouch P, Deeks SG, Havlir DV, McQuaid K, Sinclair E, Wong JK . The distribution of HIV DNA and RNA in cell subsets differs in gut and blood of. *J. Infect. Dis.* 2013;*208*: 1212–1220.


17. Thompson CG, Gay CL, Kashuba ADM . HIV Persistence in Gut-Associated Lymphoid Tissues: Pharmacological Challenges and Opportunities. *AIDS Res. Hum. Retroviruses* 2017;33: 513–523.
18. Augustin M, Horn C, Ercanoglu MS, Bondet V, Suarez I, Chon S-H, Nierhoff D, Knops E, Heger E, Oette M, Klein F, Fätkenheuer G, Duffy D, Müller-Trutwin M, Lehmann C . Treasure hunt: HIV DNA in distinct subsets in the blood, the terminal ileum, and rectum. 2019; Abstract 335, Conference on Retroviruses and Opportunistic Infections. Seattle, USA
19. van Marle G, Gill MJ, Kolodka D, McManus L, Grant T, Church DL Compartmentalization of the gut viral reservoir in HIV-1 infected patients. *Retrovirology* 2007; 4:87.
20. Lerner P., Guadalupe M, Donovan R, Hung J, Flamm J, Prindiville T, Sankaran-Walters S, Syvanen M, Wong JK, George MD, Dandekar S. The gut mucosal viral reservoir in HIV-infected patients is not the major source of rebound plasma viremia following interruption of highly active antiretroviral therapy. *J. Virol.* 2011;85: 4772–4782.
21. Imamichi H, DeGray G, Dewar RL, Mannon P, Yao M, Chairez C, Sereti I, Kovacs JA . Lack of Compartmentalization of HIV-1 Quasispecies Between the Gut and Peripheral Blood Compartments. *J Infect Dis.* 2011; 204: 309–314
22. Rozera G , Abbate I, Vlasi C, Giombini E, Lionetti R, Selleri M, Zaccaro P, Bartolini B, Corpulongo A, D'Offizi G, Baiocchini A, Del Nonno F, Ippolito G, Capobianchi MR. Quasispecies Tropism and Compartmentalization in Gut and Peripheral Blood During Early and Chronic Phases of HIV-1 Infection: Possible Correlation With Immune Activation Markers. *Clin Microbiol Infect.* 2014;20:157-166
23. Evering TH, Mehandru S, Racz P, Tenner-Racz K, Poles MA, Figueroa A, Mohri H, Markowitz M. Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection. *PLoS Pathog.* 2012; 8: e1002506.
24. Josefsson L, von Stockenström S, Faria NR, Sinclair E, Bacchetti P, Killian M, Epling L, Tan A, Ho T, Lemey P, Shao W, Hunt PW, Somsouk M, Wylie W, Douek DC, Loeb L, Custer J, Hoh R, Poole L, Deeks SG, Hecht F, Palmer S The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time. *Proc. Natl. Acad. Sci. U. S. A.* 2013;110: E4987-4996.
25. Papuchon J, Pinson P, Lazaro E, Reigadas S, Guidicelli G, Taupin J-L, Neau D, Fleury H . Resistance mutations and CTL epitopes in archived HIV-1 DNA of patients on antiviral treatment: toward a new concept of vaccine. *PLoS One* 2013; 8: e69029.
26. Papuchon J, Pinson P, Guidicelli G-L, Bellecave P, Thomas R, LeBlanc R, Reigadas S, Taupin J-L, Baril JG., Routy JP, Wainberg M Fleury H; Provir/Latitude 45 study group . Kinetics of HIV-1 CTL epitopes recognized by HLA I alleles in HIV-infected individuals at times near primary infection: the Provir/Latitude45 study. *PLoS One* 2014;9: e100452.
27. Tumiotto C, Alves BM, Recordon-Pinson P, Jourdain M, Bellecave P, Guidicelli G-L, Visentin J, Bonnet F, Hessamfar M, Neau D, Sanchez J, Brander C, Sajadi M, Eyzaguirre L, Soares EA, Routy JP, Soares MA, Fleury H . Provir/Latitude 45 study: A step towards a multi-epitopic CTL vaccine designed on archived HIV-1 DNA and according to dominant HLA I alleles. *PLoS One* 2019;14: e0212347.
28. Gosselin, A, Wiche Salinas TR, Planas D, Wacleche VS, Zhang Y, Fromentin R, Chomont N, Cohen EA, Shacklett B., Mehraj V, Ghali MP, Routy JP, Ancuta P . HIV persists in CCR6+CD4+ T cells from colon and blood during antiretroviral therapy. *AIDS* 2017; 31: 35–48.
29. Ode H, Matsuda M, Matsuoka K, Hachiya A, Hattori J, Kito Y, Yokomaku Y, Iwatani Y, Sugiura W . Quasispecies Analyses of the HIV-1 Near-full-length Genome With Illumina MiSeq. *Front. Microbiol.* 2015; 6: 1258.
30. Alves BM, Siqueira JD, Garrido MM, Botelh, OM, Prellwitz IM, Ribeiro SR, Soares EA, Soares MA . Characterization of HIV-1 Near Full-Length Proviral Genome Quasispecies from Patients with Undetectable Viral Load Undergoing First-Line HAART Therapy. *Viruses* 2017;9:pii: E392.
31. Bellecave P, Recordon-Pinson P, Fleury H . Evaluation of Automatic Analysis of Ultradeep Pyrosequencing Raw Data to Determine Percentages of HIV Resistance Mutations in Patients Followed-Up in Hospital. *AIDS Res. Hum. Retroviruses* 2016;32: 85–92.
32. Letunic I, Bork P . Interactive tree of life (iTOL) v3: an online tool for the display and annotation of phylogenetic and other trees. *Nucleic Acids Res.* 2016; 44: W242-245.
33. Palmer S Kearney, M, Maldarelli F, Halvas EK, Bixby CJ, Bazmi H, Rock D, Falloon J, Davey RTJ, Dewar RL, Metcalf JA, Hammer S, Mellors JW, Coffin JM. . Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. *J. Clin. Microbiol.*2005; 43: 406–413.
34. Bruner KM, Murray AJ, Pollack RA, Soliman MG, Laskey SB, Capoferri AA, Lai J, Strain MJ, Lada SM, Hoh R, Ho Y-C, Richman DD, Deeks SG, Siliciano JD, Siliciano RF. Defective proviruses rapidly accumulate during acute HIV-1 infection. *Nat Med.* 2016; 22: 1043–1049.
35. Pollack RA, Jones RB, Perteau M, Bruner KM, Martin AR, Thomas AS, Capoferri AA, Beg SA, Huang S-H, Karandish S, Hao H, Halper-Stromberg E, Yong PC, Kovacs C, Benko E, Siliciano RF, Ho Y-C. Defective HIV-1 proviruses are expressed and can be recognized by cytotoxic T lymphocytes which shapes the proviral landscape. *Cell Host Microbe.* 2017; 21:494–50636. Tumiotto C, Riviere L, Bellecave P, Recordon-Pinson P, Vilain-Parce A, Guidicelli G-L, Fleury H 2. Sanger and Next-Generation Sequencing data for characterization of CTL epitopes in archived HIV-1 proviral DNA. *PLoS One* 2017;12: e0185211.
37. Tamura K, Nei M, Kumar S . Prospects for inferring very large phylogenies by using the neighbor-joining method. *Proc Natl Acad Sci U S A.* 2004;101:11030-5.
38. Kumar S, Stecher G, Tamura K . MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets. *Mol Biol Evol* 2016;33:1870-4.




Patient 3




Patient 5A




Patient 5




Patient 8




Patient 10




Patient 11



Patient 12



Patient 13



Patient 14

Figure 1 : Phylogenetic trees of the NGS sequences amplified from HIV-1 proviral DNA extracted from PBMC (blue) and GALT (red) samples for all the patients. The same reference sequences were used for all trees and are notified in black. The trees are rooted on N sequences. The bootstrap values greater than 50 are indicated on the branches.




Figure 2 : Phylogeny of RT sequences obtained by NGS and SGS from PBMC and GALT of patients 10 and 5A. The NGS sequences are in black and not detailed in PBMC or GALT (please refer to Figure1). Symbols denote sampling location and patients : patient 5A PBMC (red star), patient 5A GALT (red square), patient 10 PBMC (green star), patient 10 GALT (green square)